Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

METRONIDAZOLE

All products: not a benefit

Flagyl · DIN 01926853 · 500mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled pre market since 2024-05-15 — choose a marketed DIN from the same-category list.Discontinued 2024-05-15 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled pre market since 2024-05-15 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled pre market since 2024-05-15 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Flagyl · DIN 01926853 Manufacturer: Sanofi-Aventis Canada Inc.; listing date 1996-10-01 Daily cost (source): $0.8217 Health Canada: Cancelled pre market since 2024-05-15 · brand FLAGYL · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Flagyl: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12221 · Verify on the e-Formulary ↗ (DIN 01926853)

Source record
DIN 01926853: Flagyl Raw flags: notABenefit=Y, sec3=Y Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id SAC Source form: Cap; strength: 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926853 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12221
Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739 Auro-Metronidazole · DIN 02470284 · $0.2739 M-Metronidazole · DIN 02519755 · $0.2739 Metronidazole · DIN 02518767 · $0.2739 Metronidazole · DIN 02534592 · $0.2739 PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: discontinued (2023-01-31, reported by ODAN LABORATORIES LTD); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926853
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled pre market since 2024-05-15 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:32 Trichomonacides) and how they are covered
No products matched this class search: “08:32”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications APO-METRONIDAZOLE TABLETS (Metronidazole Tablets) is indicated for: Bacterial Vaginosis Metronidazole is indicated for the treatment of bacterial vaginosis. Protozoal Infections • Trichomonal infections in men as well as in women (protozoal infection caused by Trichomonas vaginalis). • Hepatic and intestinal amebiasis. • Giardiasis. Bacterial Infections Treatment: Culture and susceptibility studies should be performed to determine the causative organisms and their susceptibility to metronidazole. Based on clinical judgment and anticipated bacteriological findings, therapy may be started while awaiting the results of these tests. However, modification of the treatment may be necessary once these results become available. In mixed aerobic and anaerobic infections, consideration should be given to the concomitant administration of an antibiotic appropriate for the treatment of the aerobic component of the infection. See 7 Warnings and Precautions, General. Metronidazole has also been used in the treatment of a small number of cases of brain or lung infections (some with abscesses) caused by anaerobic bacteria. Prophylaxis: If there are signs of infections, spe… https://pdf.hres.ca/dpd_pm/00084527.PDF PM date: 2026-04-20 Source product: APO-METRONIDAZOLE TABLETS; DIN 00545066; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Flagyl · DIN 01926853 Shortage status: discontinued (2023-01-31, reported by ODAN LABORATORIES LTD); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926853

Check this DIN again

Other review policies

For Flagyl: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026